A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-29 and is reviewed periodically as new material appears.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
The duplication events provided material for neofunctionalization to create the novel toxin genes, while gene loss influenced speciation and helped lead to such a wide variety of "chemical cocktails" in rattlesnake venoms. The prevailing theory for the driving force of this evolution is directional selection, where efficacy on prey is selected for. Diversity in prey leads to less specificity in toxins, while highly specialized toxins are more likely to develop when there are few key prey species. However, recently, balancing selection has been indicated to better explain the maintenance of adaptive genetic diversity in venom-related genes, potentially allowing for the rattlesnakes to better keep up in the evolutionary arms race with their prey. Older snakes possess more potent venom, and larger snakes are frequently capable of storing larger volumes of it.
The U.S. launched a military campaign against Yemen in mid-March 2025, which it said was directed at Houthi military and strategic targets. The attacks killed 153 civilians and wounded 243 more, according to the Pentagon's own assessment. The deaths included women and children, according to the Houthis. The group, backed by Iran, state that their operations, which have affected global trade, are in solidarity with Palestinians in Gaza.
=== Trials of procedures === Similarly to drugs, medical or surgical procedures may be subjected to clinical trials, such as comparing different surgical approaches in treatment of fibroids for subfertility. However, when clinical trials are unethical or logistically impossible in the surgical setting, case-controlled studies will be replaced.
BioDuro provides end-to-end CRDMO services spanning early discovery through clinical development. Rather than list individual assays or sub-services, the company groups its offerings into several major business units.
Sources: en.wikipedia.org
The physiological role for responses to these, and several other glycoprotein hormones, is not fully understood, although it is likely that ACTH is bifunctional, like PTH, supporting bone formation with periodic spikes of ACTH, but causing bone destruction in large concentrations. In mice, mutations that reduce the efficiency of ACTH-induced glucocorticoid production in the adrenals cause the skeleton to become dense (osteosclerotic bone).
== External links == Cartilage.org, International Cartilage Regeneration & Joint Preservation Society KUMC.edu Archived 2011-04-08 at the Wayback Machine, Cartilage tutorial, University of Kansas Medical Center Bartleby.com, text from Gray's anatomy MadSci.org, I've heard 'Ears and nose do not ever stop growing.' Is this false? CartilageHealth.com, Information on Articular Cartilage Injury Prevention, Repair and Rehabilitation About.com Archived 2011-07-07 at the Wayback Machine, Osteoarthritis Cartilage types[link removed] Different cartilages on TheFreeDictionary Cartilage photomicrographs
ColVI plays an important role in cancer by acting as a chemotherapy resistance modulator. ColVI inhibits oxidative damage and apoptosis. ColVI regulates cell differentiation and autophagic machinery. With the assistance of other collagens, proteoglycans, matrilineal, fibronectins, and glycoproteins, ColVI anchors the basement membrane of the skin to the extracellular matrix.
== Mechanism == Radioluminescence occurs when an incoming particle of ionizing radiation collides with an atom or molecule, exciting an orbital electron to a higher energy level. The particle usually comes from the radioactive decay of an atom of a radioisotope, an isotope of an element which is radioactive. The electron then returns to its ground energy level by emitting the extra energy as a photon of light. A chemical that releases light of a particular color when struck by ionizing radiation is called a phosphor. Radioluminescent light sources usually consist of a radioactive substance mixed with, or in proximity to, a phosphor.
== Comparisons with other drugs for type 2 diabetes == A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.